A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer.
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS6093-TPS6093
◽
Keyword(s):
Phase 1B
◽
Keyword(s):
2017 ◽
Vol 93
(1105)
◽
pp. 704-709
◽
Keyword(s):
Keyword(s):
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. e16011-e16011
Keyword(s):
Keyword(s):
Keyword(s):